Healthcare wasn’t a top focus for President Obama in last night’s State of the Union address, only briefly referencing the Affordable Care Act, the Administration’s Ebola response, and proposing a new initiative on precision medicine “to bring us closer to curing diseases like cancer and diabetes.”
Encouragingly, the president also acknowledged the importance of US-based research, stating, “21st century businesses will rely on American science, technology, research, and development. I want the country that eliminated polio and mapped the human genome to lead a new era of medicine — one that delivers the right treatment at the right time.” This is a critical area to support and nurture as GSK seeks to tackle some of the world’s most challenging, and deadly, diseases.
In a separate document released by the White House, a proposal was announced to nearly double federal funding for antibiotics research as well as funding the BRAIN Initiative (Brain Research through Advancing Innovative Neurotechnologies), areas in which GSK is helping lead the way.
As we embark on 2015, we are committed to working with leaders in Washington to support policies that encourage a positive, patient-centered healthcare environment, as well as policies that recognize and encourage biopharmaceutical innovation.